NCT05503667View on ClinicalTrials.gov

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

October 1, 2023

Study Completion Date

December 31, 2028

Conditions
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Interventions
DRUG

Furmonertinib

Furmonertinib 80 mg/day for 16 weeks

DRUG

Bevacizumab

bevacizumab 400 mg/4 weeks i.v. for 4 times

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER